The 2026 Antidepressant Master Matrix: A Patient’s Guide to Mechanisms & Side Effects

Navigating the landscape of modern depression psychopharmacology can feel overwhelming. With dozens of medications available, ranging from classic SSRIs to novel NMDA receptor antagonists and selective multi-modal modulators, finding the right treatment plan requires precision. Far too often, generic medical websites group these diverse compounds into broad paragraphs that skip over the crucial nuances of receptor selectivity, kinetic properties, and metabolic variances.

To provide clear, unhurried, and evidence-based clarity, I have created the Antidepressant Clinical Comparison Matrix below.

This reference guide is designed to cut through the noise, breaking down common medications by their precise pharmacological classes, primary therapeutic targets, and notable side-effect profiles. Whether you are investigating an optimal medication transition, looking to bypass partial treatment resistance, or reviewing cutting-edge, newly approved mechanisms, this chart serves as a roadmap for your mental health.

I have omitted many older antidepressants such as MAO-Is and TCAs, as they are rarely used. However, they remain available and should always be considered for cases of difficult-to-treat depression. Nor have I addressed ways in which these compounds can be combined, though many of them can be to great effect.

As always, this information is not meant to direct your treatment. While informational and vetted by a board-certified psychiatrist, it is still always best to bring this information to your psychiatrist for discussion and treatment planning, rather than making those decisions on your own.

Medication (Generic / Brand)	Class	Primary Targets / Mechanism	Notable Side-Effect Profile	Clinical Pearls & Distinctions
Escitalopram Lexapro	SSRI	Serotonin (5-HT) Reuptake	Mild initial GI upset Sexual dysfunction Dose-dependent QTc prolongation risk	Highly selective for the serotonin transporter (SERT). Noted for a very clean drug-drug interaction profile due to minimal CYP450 enzyme inhibition. Often chosen as a reliable, predictable baseline for generalized anxiety.
Citalopram Celexa	SSRI	Serotonin (5-HT) Reuptake	Moderate sedation/fatigue Sexual dysfunction	The racemic precursor to escitalopram. Features a mixture of R- and S-enantiomers; the R-enantiomer actively contributes to antihistaminic properties, leading to a slightly higher side-effect burden and stricter dosing caps (max 20mg in elderly) to avoid dangerous QTc cardiac intervals.
Sertraline Zoloft	SSRI	5-HT Reuptake Weak Dopamine (DA) Reuptake	Higher rate of initial GI distress Early activation or insomnia	An exceptionally safe choice for cardiovascular patients post-MI and throughout pregnancy or lactation. Its subtle dopamine transport inhibition can occasionally support executive function and counteract psychomotor slowing.
Fluoxetine Prozac	SSRI	5-HT Reuptake 5-HT2C Antagonism	Anxiety, restlessness, or jitteriness Insomnia Weight-neutral to mild weight loss early on	Features an extraordinarily long half-life (parent drug 2-3 days; active metabolite up to 2 weeks). This virtually eliminates severe discontinuation syndrome. 5-HT2C antagonism downregulates GABA, releasing dopamine and norepinephrine into the prefrontal cortex to improve focus and energy. Potent CYP2D6 inhibitor.
Paroxetine Paxil	SSRI	5-HT Reuptake Muscarinic (M1) Antagonism Weak NOS Inhibition	Significant sedation and fatigue Highest rates of weight gain & sexual dysfunction Anticholinergic effects (dry mouth, constipation) Severe discontinuation syndrome	The most anticholinergic and sedating SSRI due to its M1 receptor binding. It has a short half-life with non-linear pharmacokinetics, making missed doses incredibly disruptive. Highly prone to causing severe withdrawal symptoms. Strong CYP2D6 inhibitor; generally avoided in pregnancy due to minor cardiac risks. A newer extended-release formulation can help mitigate some of the side effects.
Duloxetine Cymbalta	SNRI	5-HT & Norepinephrine (NE) Reuptake	Nausea, dry mouth, heavy sweating Dose-dependent blood pressure spikes Intense discontinuation profile	Provides a balanced dual inhibition of both serotonin and norepinephrine transporters across its entire dosing spectrum. Widely utilized and FDA-approved for comorbid chronic pain conditions, diabetic neuropathy, and fibromyalgia due to its amplification of descending spinal inhibitory pathways.
Venlafaxine Effexor XR	SNRI	5-HT Reuptake (Low doses) NE Reuptake (High doses)	Sweating, vivid dreams, nausea Diastolic hypertension risk at high doses Profound withdrawal symptoms	Operates purely as an SSRI at lower dosages (75mg). Norepinephrine reuptake inhibition only becomes clinically meaningful at higher doses (≥150mg). Requires highly meticulous tapering protocols, frequently utilizing a cross-titration Prozac bridge to avoid severe dizziness and brain zaps.Should almost never be given in the original IR formulation to avoid intra-day withdrawal effects.
Desvenlafaxine Pristiq	SNRI	5-HT & NE Reuptake Inhibition	Nausea, dry mouth, insomnia Early, acute discontinuation symptoms if missed	The active major metabolite of venlafaxine. Unlike its parent drug, desvenlafaxine inhibits both SERT and NET robustly right at its starting dose (50mg). Because it bypasses CYP2D6 hepatic metabolism completely, it features incredibly predictable blood levels and zero drug interactions via that major pathway.
Levomilnacipran Fetzima	SNRI	NE & 5-HT Reuptake (NE Preferential)	Nausea, sweating, erectile dysfunction Higher risk of dose-dependent tachycardia & hypertension Urinary hesitation	The 100% active enantiomer of milnacipran. Highly unique among modern SNRIs due to its extreme, **preferential selectivity for norepinephrine reuptake over serotonin** (roughly 2-fold greater potency for NET than SERT). Exceptional for treating severe motivational deficits, profound lethargy, and psychomotor retardation, but requires close monitoring of heart rate and blood pressure.
Gepirone Exxua	Atypical / Azapirone	Selective 5-HT1A Full/Partial Agonist	Dizziness, nausea, headache Strict FDA warning: QTc prolongation Zero sexual side effects / Weight neutral	An extended-release formulation binding exclusively to 5-HT1A receptors. Completely avoids the metabolic and sexual issues of older classes. However, **FDA guidelines mandate a strict baseline EKG and regular corrective EKG monitoring during titration.** Because of this heavy requirement for outpatient medical monitoring, it is clinically impractical for most typical telehealth or standard psychiatric settings.
Bupropion Wellbutrin XL	Atypical	DA & NE Reuptake Inhibition (NDRI)	Jitteriness, insomnia, mild tremor Zero sexual side effects Zero weight gain / Weight neutral	Lacks serotonergic mechanism entirely, avoiding sexual dysfunction and metabolic weight issues. Ideal for managing lethargy, psychomotor retardation, and comorbid executive dysfunction/ADHD. Strictly contraindicated in active or historical eating disorders (bulimia/anorexia) or active seizure disorders due to a dose-dependent reduction in the seizure threshold. Perhaps the most commonly used adjunctive medication, often paired with an SSRI.
Mirtazapine Remeron	Atypical	α2-Adrenergic Antagonism 5-HT2, 5-HT3, & H1 Antagonism	Pronounced sedation (worse at low doses) Appetite stimulation & weight gain Dry mouth	Features an inverse dosing logic: lower doses (7.5mg–15mg) are intensely sedating due to dominant H1 histaminergic binding. Higher doses (30mg–45mg) trigger robust noradrenergic firing that actively counteracts the sedation. Highly effective for treatment-resistant depression presenting with severe insomnia, nausea (via 5-HT3 blockade), or cachexia.
Dextromethorphan / Bupropion Auvelity	Atypical / NMDA	NMDA Receptor Antagonist Sigma-1 Agonist / CYP2D6 Inhibition	Dizziness, headache, dry mouth Mild elevation in blood pressure Hyperhidrosis (sweating)	The first oral rapid-acting antidepressant. Dextromethorphan acts as an NMDA antagonist and glutamate modulator, while the bupropion component serves primarily as a potent CYP2D6 inhibitor to slow down dextromethorphan's metabolism, extending its bioavailability. Clinically demonstrates significant symptom reduction within just 1 week.
Zuranolone Zurzuvae	Neurosteroid	GABA-A Receptor Positive Allosteric Modulator	Somnolence, dizziness, fatigue Diarrhea Black box warning for driving impairment	**FDA-approved specifically for Postpartum Depression (PPD).** Unlike monoamine therapies that take weeks to downregulate receptors, zuranolone targets synaptic and extrasynaptic GABA-A receptors to rapidly rebalance neuroactive steroid crashes post-delivery. Prescribed strictly as a rapid, **14-day acute oral course** taken once daily in the evening with fat-containing food.
Nortriptyline Pamelor	TCA	Potent NE Reuptake Inhibition Moderate 5-HT Reuptake / H1, M1 Blockade	Anticholinergic (blurred vision, dry mouth, urinary retention) Orthostatic hypotension, sedation High toxicity risk in acute overdose	A secondary amine tricyclic antidepressant, making it far more noradrenergic and much less anticholinergic/sedating than its tertiary amine parent, amitriptyline. Features a strict "therapeutic window" (50-150 ng/mL).
Vortioxetine Trintellix	SMS	5-HT Reuptake 5-HT1A Full Agonism / 5-HT3, 5-HT7 Antagonism	High initial rate of transient nausea Extremely low sexual side effects Weight-neutral profile	A sophisticated multimodal serotonin modulator. Direct sub-receptor targeting downstream increases concentrations of acetylcholine, histamine, and dopamine within the prefrontal cortex. Distinctly supported by clinical data demonstrating measurable improvements in objective cognitive deficits (processing speed, executive focus).
Aripiprazole Abilify	MDD Adjunct	D2 & 5-HT1A Partial Agonism 5-HT2A Antagonism	High rate of Akathisia (inner restlessness) Mild, dose-dependent activation or insomnia Risk of mild metabolic changes/weight gain	The classic, robust dopamine partial agonist approved for adjunctive MDD. It features a high intrinsic activity at the D2 receptor, which effectively amplifies sluggish dopamine pathways in depression. However, its tight binding kinetics carry a significantly higher clinical risk of akathisia compared to newer modulators, requiring careful low-dose titration (typically 2mg–5mg).
Brexpiprazole Rexulti	MDD Adjunct	D2 & 5-HT1A Partial Agonism 5-HT2A & α1B/2C Antagonism	Mild weight gain Akathisia (significantly lower than aripiprazole) Somnolence	FDA-approved specifically as an adjunctive treatment for MDD. It acts as a serotonin-dopamine activity modulator (SDAM). Compared to aripiprazole, it features lower intrinsic activity at the D2 receptor and more potent 5-HT1A/2A targeting, resulting in a much lower incidence of treatment-limiting restlessness and agitation.
Cariprazine Vraylar	MDD Adjunct	D3 & D2 Partial Agonism (D3 Preferential) 5-HT1A Partial Agonism / 5-HT2B Antagonism	Akathisia or restlessness Extrapyramidal symptoms (EPS) Mild, generally weight-neutral profile	FDA-approved as an adjunctive treatment for MDD. It is highly unique due to its massive, preferential selectivity for the **D3 receptor** over D2. This intense D3 partial agonism uniquely modulates mood, motivation, and reward pathways, making it particularly powerful for profound anhedonia and treatment-resistant depressive phases. Features an exceptionally long half-life, requiring careful titration and monitoring of emergent side effects.
Lumateperone Caplyta	Bipolar / MDD Modulator	Potent 5-HT2A Antagonism Postsynaptic D2 Modulation / SERT Inhibition	Somnolence/sedation (early on) Dry mouth Exceptional metabolic & motor safety profile	Widely used for unipolar MDD (adjunct) and extensively FDA-approved for Bipolar I/II depression. It features a completely unique '60-fold' binding preference for 5-HT2A over D2 receptors, providing powerful antidepressant action with virtually **zero metabolic disruptions, zero weight gain, and no extrapyramidal symptoms.** An incredibly elite option for highly sensitive patients.
L-Methylfolate Deplin (15mg)	Medical Food	Trimonoamine Trimethylation Optimizer Bypasses MTHFR Enzyme Rate-Limiting Step	Extremely well-tolerated Rare mild GI upset or rash **No monoaminergic side effects**	A regulated medical food **designed specifically for optimizing response to traditional antidepressants.** It provides the only form of folate capable of crossing the blood-brain barrier to serve as a mandatory co-factor for synthesizing serotonin, norepinephrine, and dopamine. Uniquely critical for patients with genetic polymorphism deficiencies of the L-methylfolate (MTHFR) enzyme who exhibit partial or complete resistance to SSRIs/SNRIs.
Lithium Carbonate Eskalith / Lithobid	Monotherapy / Adjunct	Cationic Ion Transport Modulation Intracellular Signaling (GSK-3 & IPP Inhibition)	Fine hand tremor, polyuria/polydipsia (increased thirst) Mild cognitive slowing or GI distress Long-term risk of hypothyroidism & renal dysfunction Acute toxicity risk (ataxia, slurred speech, confusion)	A highly effective agent utilized both as a foundational monotherapy and as a **premier adjunctive strategy to optimize traditional antidepressants in treatment-resistant depression.** It is one of the only psychiatric medications clinically proven to directly reduce suicidal ideation and behavior. Features a **narrow therapeutic index requiring mandatory, regular serum blood monitoring** (typically aiming for 0.6–1.2 mEq/L for maintenance, or lower ranges for unipolar augmentation) alongside baseline and tracking labs for TSH and renal function (Cr/GFR).